Compare Fubotv Inc (FUBO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fubotv Inc trades at $9.38 (market cap $1.02B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.1× Fubotv Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FUBO | RXRX | |
|---|---|---|
Market Cap | $1.02B | $2.14B |
Volume | 978,631 | 30,789,535 |
Sector | Media | Health |
52-Week High | $48.96 | $6.79 |
52-Week Low | $8.09 | $2.84 |
Typical Hold Time | 35 Days | 22 Days |
Enterprise Value | $1.19B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.25, up 4.76% today, showing technical bearish signals with mixed earnings performance. The company reported Q2 2026 EPS of -$0.25, beating expectations, but missed in Q4 2025. Revenue growth has been strong, reaching $1.62B in 2024 with improving profit margins. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a speculative opportunity with deep valuation discounts (P/E 2.43, P/S 0.19) but faces execution risks amid persistent cash burn. Analyst consensus is mixed with 47% buy ratings and $63.38 price target, representing significant upside potential if turnaround succeeds. Key risks include competitive pressure and path to sustained profitability.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
